Genetically Engineered Bacteria as a Promising Therapeutic Strategy Against Cancer: A Comprehensive Review
Biotechnology and Applied Biochemistry · 2025-10 · 72 (5) · 1458-1476
DOI: 10.1002/bab.2738 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biotechnology and Applied Biochemistry, online erschienen am 21.02.2025. Verfasst von Zahra Zahedifard und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran. Hauptthemen laut MEDLINE: Neoplasms, Genetic Engineering, Microorganisms, Genetically-Modified, Bacteria. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 264 Literaturangaben.
Abstract (Originalsprache)
As a significant cause of global mortality, the cancer has also economic impacts. In the era of cancer therapy, mitigating side effects and costs and overcoming drug resistance is crucial. Microbial species can grow inside the tumor microenvironment and inhibit cancer growth through direct killing of tumor cells and immunoregulatory effects. Although microbiota or their products have demonstrated anticancer effects, the possibility of acting as pathogens and exerting side effects in certain individuals is a risk. Hence, several genetically modified/engineered bacteria (GEB) have been developed to this aim with ability of diagnosing and selective targeting and destruction of cancers. Additionally, GEB are expected to be considerably more efficient, safer, more permeable, less costly, and less invasive theranostic approaches compared to wild types. Potential GEB strains such as Escherichia coli (Nissle 1917, and MG1655), Salmonella typhimurium YB1 SL7207 ( aroA gene deletion), VNP20009 (∆msbB/∆purI) and ΔppGpp (P Tet and P BAD ), and Listeria monocytogenes Lm at ‐LLO have been developed to combat cancer cells. When used in tandem with conventional treatments, GEB substantially improve the efficacy of anticancer therapy outcomes. In addition, public acceptance, optimal timing (s), duration (s), dose (s), and strains identification, interactions with other strains and the host cells, efficacy, safety and quality, and potential risks and ethical dilemmas include major challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran.
- Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
ORCID-Profile: Zahra Zahedifard, Shirin Mahmoodi, Abdolmajid Ghasemian
Zitieren
APA
Zahedifard, Z., Mahmoodi, S., & Ghasemian, A. (2025). Genetically Engineered Bacteria as a Promising Therapeutic Strategy Against Cancer: A Comprehensive Review. Biotechnology and Applied Biochemistry, 72(5), 1458-1476. https://doi.org/10.1002/bab.2738
Vancouver
Zahedifard Z, Mahmoodi S, Ghasemian A. Genetically Engineered Bacteria as a Promising Therapeutic Strategy Against Cancer: A Comprehensive Review. Biotechnology and Applied Biochemistry. 2025;72(5):1458-1476. doi:10.1002/bab.2738
BibTeX
@article{Zahedifard2025,
author = {Zahedifard, Zahra and Mahmoodi, Shirin and Ghasemian, Abdolmajid},
title = {Genetically Engineered Bacteria as a Promising Therapeutic Strategy Against Cancer: A Comprehensive Review},
journal = {Biotechnology and Applied Biochemistry},
year = {2025},
volume = {72},
number = {5},
pages = {1458--1476},
doi = {10.1002/bab.2738}
}
EUVIMED